Further to the results of prior studies published last year, Almirall, the international pharmaceutical company based in Spain, announced new Phase II multi-dose study results demonstrating that its novel once-daily, inhaled, long-acting beta-agonist (LABA) -LAS100977-, for the treatment of bronchoconstriction in asthmatic patients, shows fast-acting and 24-hour efficacy, as well as a good safety and tolerability profile in patients during multiple dose administrations.

Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, today announced the successful completion of preclinical studies (in-vitro and in-vivo in mice) on ANAVEX 2-73, a novel sigma-1 receptor agonist for the treatment of Alzheimer's disease.

Protherics PLC, the international biopharmaceutical company focused on critical care and cancer, today announces that its placebo-controlled phase 2b Digoxin Immune Fab (DIF) Efficacy Evaluation in Pre-eclampsia ("DEEP") study in severe pre-eclampsia has met one of its two primary endpoints.

The Medicines Company (NASDAQ: MDCO) announced that its investigational agent, Cleviprex(TM) (clevidipine butyrate injectable emulsion), rapidly achieved and maintained blood pressure control in patients with renal dysfunction (RD) and patients with acute heart failure (AHF), according to two new analyses from the Phase III trial VELOCITY(1) presented at the annual meeting of the Society of Clinical Care Medicine (SCCM).

Pharmion Corporation (Nasdaq: PHRM) and MethylGene Inc (TSX: MYG) announced maturing data from the Phase 1/2 study investigating the combined use of MGCD0103, a novel, isotype-selective histone deacetylase (HDAC) inhibitor, and Vidaza(R) (azacitidine for injection) in patients with myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML).

The Journal of the American Medical Association (JAMA) today published one-year results of the ACUITY trial, which show that acute coronary syndrome (ACS) patients treated with Angiomax(R) (bivalirudin) alone had similar rates of ischemic clinical outcomes compared with a more complicated treatment regimen of heparin plus a glycoprotein IIb/IIIa inhibitor (GP IIb/IIIa).[1]

Pharmion Corporation (Nasdaq: PHRM) today announced the initiation of an international pivotal Phase 3 clinical trial evaluating amrubicin, the Company's third-generation synthetic anthracycline, in the treatment of second-line small cell lung cancer (SCLC). The randomized, controlled, multi-center study will compare amrubicin to topotecan, the only approved chemotherapy for second-line treatment of SCLC in the US and EU. Enrollment in the study of 480 patients is underway.